^
NOTCH1 mutation
Prolymphocytic Leukemia
ibrutinib
Resistant: C3 – Early Trials
JAK3 mutation
Prolymphocytic Leukemia
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
CDKN2A deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
STAT5B N642H
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
TCL1A rearrangement
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
RAD50 Y625
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
ATM D2721N
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
PAK4 deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
BRAF V600E
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
BRAF V600E
Prolymphocytic Leukemia
venetoclax
Resistant: C4 – Case Studies
BRAF V600E
Prolymphocytic Leukemia
dasatinib
Resistant: C4 – Case Studies
BRAF V600E
Prolymphocytic Leukemia
vemurafenib
Sensitive: C4 – Case Studies